
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd's positive outlook is supported by the potential for securing additional human licensing deals in 2026, which could enhance topline revenue growth, especially given the company's pioneering focus on circulating cell-free nucleoproteins in liquid biopsies. Encouraging early-stage cancer detection results, including detection rates of up to 100% for certain stages, bolster confidence in the Nu.Q platform's utility in clinical settings, particularly regarding acute care and chronic disease monitoring. Furthermore, the technology's ability to produce over 99% pure circulating tumor DNA datasets marks a significant advancement in detection accuracy, suggesting a promising trajectory for clinical adoption and revenue generation as larger validation studies are conducted.
Bears say
VolitionRX faces significant risks that contribute to a negative outlook on its stock, including possible failures in clinical development of its diagnostic products, securing necessary license agreements, and achieving market traction. The company's net loss of $23.4 million, translating to a loss of $0.22 per share, highlights ongoing financial challenges. Additionally, concerns regarding dilution, going concern, and potential delisting add further uncertainty to the company's financial stability and future prospects.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares